Health Trials

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

ConditionsB-cell LymphomaNon-Hodgkin LymphomaB-cell MalignancyChronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Follicular LymphomaMantle Cell LymphomaMarginal Zone LymphomaLarge B-cell Lymphoma
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorCRISPR Therapeutics AG

About this trial

This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.

Eligibility criteria

Qualifiers

Age ≥18 years.

Refractory or relapsed B cell malignancy.

Eastern Cooperative Oncology Group performance status 0 or 1.

Adequate renal, liver, cardiac and pulmonary organ function.

Disqualifiers

Prior allogeneic hematopoietic stem cell transplant (HSCT).

Active or history of central nervous system (CNS) involvement by malignancy.

History of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement.

Presence of bacterial, viral, or fungal infection that is uncontrolled or requires IV anti-infectives.

Trial design

Treatments tested in this trial

  • CTX112

Treatment groups

120 Participants
are divided into 1 treatment group

Sponsors and collaborators

CRISPR Therapeutics AG

Lead sponsor

Source ClinicalTrials.gov